Bulletin
Investor Alert

Topics

Bristol-Myers Squibb

/marketstate/country/us

After Hours

05/14/21

BMY
Bristol Myers Squibb Co.
/zigman2/quotes/202559280/composite

$

64.83

Change

-0.05 -0.08%

Volume

Volume 580,754

Quotes are delayed by 20 min

/zigman2/quotes/202559280/composite

Previous close

$ 65.04

$ 64.88

Change

-0.16 -0.25%

Day low

Day high

$64.62

$65.29

Open

52 week low

52 week high

$54.07

$67.16

Open
12:41 p.m. May 14, 2021 - By MarketWatch Automation
12:41 p.m. May 13, 2021 - By MarketWatch Automation
12:41 p.m. May 12, 2021 - By MarketWatch Automation
12:41 p.m. May 11, 2021 - By MarketWatch Automation
12:41 p.m. May 10, 2021 - By MarketWatch Automation
12:41 p.m. May 7, 2021 - By MarketWatch Automation
12:41 p.m. May 6, 2021 - By MarketWatch Automation
3:34 a.m. May 6, 2021 - Barrons.com
Regeneron Earnings Lift Stock. Here's Why. The biotech company reported financial results early Thursday. It was the details that seemed to matter.
12:41 p.m. May 5, 2021 - By MarketWatch Automation
12:41 p.m. May 4, 2021 - By MarketWatch Automation
6:24 a.m. May 4, 2021 - Barrons.com
Pfizer Expects $26B in Covid-19 Vaccine Sales This Year After a week of disappointing earnings reports from big biopharma firms, Pfizer bucked the trend, reporting first-quarter earnings and revenue that beat Wall Street expectations.
12:42 p.m. May 3, 2021 - By MarketWatch Automation
9:19 a.m. May 3, 2021 - Barrons.com
Pfizer's Earnings Are Tuesday. Here's What to Expect. The company says its Covid-19 vaccine provides the viability of a focus on developing and acquiring drugs.
5:24 a.m. May 3, 2021 - Barrons.com
How Shareholders Missed Out on a Potential $6 Billion in Bristol Myers’ Deal for Celgene An all-or-nothing bet on drug approvals highlights the risks investors take.
12:41 p.m. April 30, 2021 - By MarketWatch Automation
9:47 a.m. April 30, 2021 - Barrons.com
Stocks Close Out April With a Whimper Even with Friday's losses, though, major benchmarks posted monthly gains after a slate of better-than-expected earnings reports.
6:30 a.m. April 30, 2021 - Barrons.com
Bristol Myers Stock Gets a Downgrade. Analyst Cites Doubts on Drug Pipeline. Morgan Stanley analyst David Risinger now rates the company at Equal-weight, down from Overweight. He cut his target for the stock price.
5:08 a.m. April 30, 2021 - Barrons.com
Amazon Rises, Clorox Dips, and Stocks Are Down Stocks look set for a lower open on Friday, as economic data from around the globe missed expectations.
12:41 p.m. April 29, 2021 - By MarketWatch Automation
5:04 a.m. April 29, 2021 - Barrons.com
Bristol Myers Squibb Stock Fell After Earnings. Here's Why. The drugmaker Bristol Myers Squibb reported earnings early Thursday that fell short of Wall Street expectations.
3:11 a.m. April 29, 2021 - By Tomi Kilgore
Bristol Myers Squibb stock falls, as profit and revenue rise but miss expectationsShares of Bristol Myers Squibb Co. shed 2.1% in premarket trading Thursday, after the drug maker reported a first-quarter profit that came up short of expectations, as the COVID-19 pandemic reduced revenue growth by 5 percentage points. The company swung to net income of $2.02 billion, or 89 cents a share, from a loss of $775 million, or 34 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share increased to $1.74 from $1.72, but missed the FactSet consensus of $1.81. Revenue grew 3% to $11.07 billion, but was shy of the FactSet consensus of $1.13 billion. Among the company's top selling drugs, Revlimid sales rose 1% to $2.94 billion and Eliquis sales grew 9% to $2.89 billion. The company estimates that excluding COVID-19-related buying patterns from the prior year period, revenue would have grown 8%. For 2021, the company affirmed its adjusted EPS guidance range of $7.35 to $7.55. The stock has gained 6.5% year to date through Wednesday, while the S&P 500 has advanced 11.4%.
Bristol Myers affirms 2021 adj. EPS outlook $7.35-$7.55
3:02 a.m. April 29, 2021
Bristol Myers Q1 revenue $11.07 bln vs. $10.78 bln a year ago; FactSet consensus $11.13 bln
3:01 a.m. April 29, 2021
Bristol Myers Q1 adj. EPS $1.74 vs. $1.72 a year ago; FactSet consensus $1.81
3:01 a.m. April 29, 2021
Bristol Myers Squibb Q1 EPS 89 cents vs. per-share loss 34 cents a year ago
3:00 a.m. April 29, 2021
12:41 p.m. April 28, 2021 - By MarketWatch Automation
10:09 a.m. April 28, 2021 - By Ciara Linnane
U.S. companies went right back to heavy use of nonstandard accounting metrics during the pandemicU.S. companies turned to an old habit during the 2020 pandemic, according to a recent report from financial data provider Calcbench.
12:42 p.m. April 27, 2021 - By MarketWatch Automation
12:41 p.m. April 26, 2021 - By MarketWatch Automation
4:13 a.m. April 26, 2021 - By Jaimy Lee
FDA to discuss whether immuno-oncology drugs with 'accelerated' approval should remain on the marketThe Food and Drug Administration advisory committee plans to hold a three-day this week to evaluate a type of quicker approval used primarily for immuno-oncology drugs that are thought to help address unmet treatment needs among people with cancer. The FDA's "accelerated approval" process requires drug makers to conduct what are called confirmatory trials to back up the limited data used to inform the initial regulatory ok. The meeting will focus on Roche Holding AG's Tecentriq; Merck & Co Inc.'s top-selling drug Keytruda, which brought in $14.3 billion in 2020; and Bristol Myers Squibb Co.'s Opdivo, which generated $6.9 billion last year. The FDA said in documents that these drugs received additional accelerated approvals to treat different types of cancers "but subsequent confirmatory trial(s) have not verified clinical benefit ... The FDA is seeking the committee's advice on next steps for each product including whether the indications should remain on the market while additional trial(s) are conducted." The meeting is scheduled for April 27 to 29.
3:55 a.m. April 26, 2021 - Barrons.com
Tesla, Apple, Amazon, Visa, GE, Exxon Mobil, and Other Stocks to Watch This Week It’s a packed week of earnings with Apple, Amazon, Tesla, Microsoft, Boeing, Exxon Mobil, Starbucks, Visa, Ford, and Comcast among 169 S&P 500 firms reporting.
3:10 p.m. April 23, 2021 - Barrons.com
How Soon Before the Chip Shortage Ends? Taiwan Semi Looks to 2022. The big chip manufacturer is ramping up capital spending to $30 bilion annually to tackle the capacity problem. That won’t happen overnight.
12:41 p.m. April 23, 2021 - By MarketWatch Automation
12:41 p.m. April 22, 2021 - By MarketWatch Automation
12:41 p.m. April 21, 2021 - By MarketWatch Automation
12:41 p.m. April 20, 2021 - By MarketWatch Automation
12:41 p.m. April 19, 2021 - By MarketWatch Automation
4:30 a.m. April 18, 2021 - Barrons.com
2 Biotech Start-Ups Are Searching for Cancer's Hidden Weaknesses Biotech startups Repare Therapeutics and Ideaya Biosciences, along with Big Pharma partners, are now leading clinical trials for new drugs.
12:41 p.m. April 16, 2021 - By MarketWatch Automation
12:41 p.m. April 15, 2021 - By MarketWatch Automation
Browse topics:

Filter results by

Location

Us (23)

Asia Pacific (2)

China (2)

Eu (2)

Europe (2)

Germany (1)

Link to MarketWatch's Slice.